Travere Therapeutics (NASDAQ:TVTX) reported second-quarter results marked by record FILSPARI demand and revenue, driven by continued growth in IgA nephropathy and an early launch in focal segmental glomerulosclerosis, or FSGS. Travere said first-pass approval rates in FSGS are ahead of those seen at a comparable point in the IgA nephropathy launch. IgA Nephropathy Demand Continues to RiseIn IgA nephropathy, Travere said demand increased sequentially despite the arrival of additional treatment options. Travere also completed enrollment in a post-transplant study evaluating FILSPARI in recurrent FSGS and recurrent IgA nephropathy, with data anticipated in 2027. R&D spending increased primarily due to HARMONY enrollment activities and pegtibatinase manufacturing, while SG&A rose with the FSGS launch and continued IgA nephropathy investments.